Your session is about to expire
← Back to Search
Imaging
MRI Screening for Prostate Cancer
N/A
Recruiting
Led By Scott Eggener, MD
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 3 years up to 15 years
Awards & highlights
Study Summary
This trial will test if MRI can spot prostate cancer earlier in high-risk men.
Who is the study for?
This trial is for men aged 18 and older who are at high risk of developing prostate cancer but have no known history of it. They should not have had any previous prostate surgery or a biopsy within the last three years, nor an MRI in that time frame. Men with metal fragments, severe claustrophobia, without a rectum, or those who've had hip replacement are excluded.Check my eligibility
What is being tested?
The study is testing if using Magnetic Resonance Imaging (MRI) can detect serious types of prostate cancer earlier and more reliably in men considered to be at high risk for this disease.See study design
What are the potential side effects?
Since the intervention involves MRI screening, there may be discomfort due to lying still during the procedure. There's also a small chance of an allergic reaction to contrast materials if used. Claustrophobic individuals might experience anxiety.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ every 3 years up to 15 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 3 years up to 15 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Malignant Neoplasms
Trial Design
4Treatment groups
Experimental Treatment
Group I: Low Risk (n=125):Experimental Treatment1 Intervention
No known germline mutation, low genetic risk score (GRS <1.5), and no known family history of prostate cancer.
Group II: High Risk- Positive Germline Mutation (n=40):Experimental Treatment1 Intervention
Men who harbor known germline mutations that have been associated with an increased risk of prostate cancer and aggressive disease (e.g. BRCA2, ATM, PALB2, etc.) with or without a known family history of prostate cancer.
Group III: High Risk- High GRS (n=40):Experimental Treatment1 Intervention
Men who harbor significantly increased disease risk based upon genetic risk score (GRS) value >1.5 with or without a known family history of prostate cancer.
Group IV: High Risk- Family History (n=45):Experimental Treatment1 Intervention
Men with a family history of prostate cancer in at least one sibling, father, uncle, or grandfather but no known increased genetic risk of prostate cancer (has no pathogenic or likely pathogenic mutation along with a low genetic risk score (GRS<1.5).
Find a Location
Who is running the clinical trial?
University of ChicagoLead Sponsor
1,004 Previous Clinical Trials
819,527 Total Patients Enrolled
Scott Eggener, MDPrincipal InvestigatorUniversity of Chicago
4 Previous Clinical Trials
462 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not had surgery or ablation for my prostate.I have had a hip replacement surgery.I have never been diagnosed with prostate cancer.I do not have a rectum.I am a man aged 18 or older.
Research Study Groups:
This trial has the following groups:- Group 1: High Risk- Positive Germline Mutation (n=40):
- Group 2: High Risk- Family History (n=45):
- Group 3: High Risk- High GRS (n=40):
- Group 4: Low Risk (n=125):
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the current enrollment capacity for this research program?
"Affirmative. Clinicaltrials.gov elucidates that this clinical trial is presently seeking volunteers, being originally posted on March 2nd 2022 and last edited November 2nd 2022. Around 250 participants are needed from one location in particular."
Answered by AI
Are there still vacancies available in this research trial?
"The review of clinicaltrials.gov's records shows that this medical trial is actively seeking volunteers to take part in the study, first posted on March 2nd 2022 and last revised November 2nd 2022."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger